HLB Life Science
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
HLB Life Science makes components for rapid diagnostic test kits, such as those used to detect infectious diseases at the point of care, and also produces disposable syringes and other medical consumables.
It supplies these products to medical device makers, laboratories, and healthcare facilities, with customers including major global diagnostics companies that use its contract manufacturing services. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across four distinct business segments: a healthcare manufacturing and services division, a biotech research and development arm, a medical device unit, and an energy business covering solar and waste-heat projects.
Summary is AI-generated and may contain errors · figures from DART filings
HLB Life Science conducts its biotech research and development activities through a subsidiary called HLB Cell, keeping that pipeline legally separate from its manufacturing operations.
HLB Life Science in five facts
What does HLB Life Science do?
HLB Life Science makes components for rapid diagnostic test kits, such as those used to detect infectious diseases at the point of care, and also produces disposable syringes and other medical consumables.
Where is HLB Life Science listed and in which sector?
HLB Life Science (Korean name: HLB생명과학) trades under KRX code 067630 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is HLB Life Science?
Its market capitalisation was US$340.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were HLB Life Science's latest annual revenue and operating profit?
For fiscal year 2025, HLB Life Science reported revenue of US$34.5M, an operating loss of US$16.6M and a net loss of US$75.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 55.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingOct 12
- Early redemption of convertible bonds (incl. overseas CBs)
HLB Life Science Co., Ltd. acquired US$439K face value of its Series 13 convertible bonds (issued August 29, 2024, maturing August 29, 2027, conversion price US$5.86 per share after adjustment) on August 31, 2026 following the bondholder's exercise of its early redemption request (put option), paying US$449K including principal and interest, leaving US$439K face value outstanding; the bonds will be deregistered with the Korea Securities Depository.
Capital raise · Aug 31 - Decision to acquire shares/equity in another company
HLB Life Science disclosed an acquisition of HLB Innovation Co., Ltd., worth US$26.1M.
M&A · Aug 28 - Early redemption of convertible bonds (incl. overseas CBs)
HLB Life Science Co., Ltd. acquired US$3.53M face value of its Series 13 convertible bonds (issued 2024-08-29, maturing 2027-08-29, conversion price US$5.65 per share) on 2026-08-14 for US$3.61M (principal plus interest) by separate agreement with the bondholder, via over-the-counter purchase, leaving US$847K of the bonds outstanding; future treatment is to be determined by the board.
Capital raise · Aug 14 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jun 18
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · May 29
- Material event report (convertible bonds)
HLB Life Science disclosed convertible bonds to raise US$6.69M, about 1.9% of its market value.
Capital raise · May 28 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 3
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 25
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
HLB Life Science reported consolidated results for FY2025: revenue of US$32.1M (−54.5% year on year), an operating loss of US$15.2M and a net loss of US$69M (from a profit a year earlier).
Earnings · Feb 20 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 19
- Material event report (exchangeable bonds)Capital raise · Jan 22